Koc et al. STAMP trial in PsA. Secukinumab+MTX+GC vs MTX+GC(+SSZ if needed). Both could go to TNF if needed. Secukinumab significantly better at week 12 but no longer at week 24. @RheumNow #ACR24 Abstr#1457 https://t.co/4TGSiUPebV https://t.co/eAANkYIpzy

• Treat-to-Target Approaches in Early Psoriatic Arthritis: Early Secukinumab vers…
• https://x.com/RichardPAConway/status/1858190864708780251/photo/1

Abst #1473 evaluated association of SJC in PROs from 2 Bimekizumab trials (bDMARD naïve vs TNFi-IR) -bDMARD naïve had less SJC at baseline -In both groups, pts w lower SJC had sustained improvement in pain and fatigue over time. #ACR24 @RheumNow https://t.co/zwxsSbga7c

• https://x.com/AdelaCastro222/status/1858180798488424715/photo/1

New agent on the block: Bimekizumab IL-17A/F inhibitor Promising clinical data in SpA - what about imaging findings? Dramatic reductions in MRI activity at SI joints seen in BKZ pt, esp when compared to trajectory of PBO pt before cross-over @RheumNow #ACR24 Abst #1757 https://t.co/ACLJx5XkyN

• https://x.com/Dr_Brian_MD/status/1858168067844383139/photo/1

#1462 🔬Rx persistence in PsA; Guselkumab (GUS) v. IL17Ai 💡 GUS (n=910) persistence @ 12 months (67%) almost 2X IL-17Ai (n=2743) (50%) ⏳ Median time to discontinuation: GUS not reached v 12.3 months for IL-17Ai. 🔴Durable therapy ❓better outcomes #ACR @RheumNow https://t.co/LfA3WygNVq

• https://x.com/CaoilfhionnMD/status/1858177527115608457/photo/1

Harkins @DrTrishHarkins et al. Novel diagnostic cytokines in treatment naive PMR. Elevations CXCL-9 (100%), MCP-1 (93%), IL-17A (83%), vs TNF (7%) and IL-6 (67%) @RheumNow #ACR24 Abstr#0881 https://t.co/DbYOn81QJH https://t.co/3eyre00D5d

• Cytokine Profile of Newly Diagnosed Patients with Isolated Polymyalgia Rheumati…
• https://x.com/RichardPAConway/status/1858157645917552730/photo/1

Half of the respondents chose #IL17i for #psoriatic #arthritis #PsA Rx for #Achilles #tendonitis Interesting as lots Of data On #enthesitis wIL23i Likely all Effective #PsA Rx helps #tenosynovitis some have ➡️ data on #efficacy ⬆️ bio rationale #ACR24 @RheumNow @ACRheum https://t.co/wzefjsfdaj

• https://twitter.com/janetbirdope/status/1857188344100221389

The post hoc analysis of the SURPASS study evaluated predictors of radiographic spinal progression in axial spondyloarthritis patients treated with IL-17A (secukinumab) or TNF inhibitors over 2 years. Key findings: - New syndesmophytes: 18.2% (SEC 150 mg), 15.8% (SEC 300 mg),… https://t.co/jke6OHdPjZ

• https://x.com/i/web/status/1858151857870315827

Factors associated w/ secukinumab response in PsA? Analysis of 2.7k pt in EuroSpA Associated w/ favorable response ❗️elevated CRP >10 mg/L ❗️fewer prev tx Associated w/ lower response: ❗️smoking ❗️higher patient global score / HAQ @RheumNow #ACR24 Abstr 2325